MetaCap

Who Owns Autolus Therapeutics Stock?

NASDAQ: AUTLHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

0.9073-0.0723 (-7.38%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Ownership breakdown

Held by institutions
56.45%
Institutional holders
106
  • Institutions 56.5%
  • Insiders 18.7%
  • Public and other 24.8%

Who owns Autolus Therapeutics stock?

Institutional investors own about 56.5% of Autolus Therapeutics's shares, spread across 106 institutions that file 13F reports. That level of institutional ownership is moderate. Insiders, including executives, directors and large founding shareholders, hold 18.73% of AUTL.

The largest institutional holders are MAK Capital One LLC (12.62%), Blackstone Inc (7.69%) and Syncona Portfolio Ltd (6.25%). Together, the top 10 institutions control 43.8% of shares outstanding. In their latest filings, 1 of the top 10 institutions increased their AUTL positions and 2 reduced them.

Summary generated from market data by MetaCap's automated system. Methodology

Top institutional holders of AUTL

Autolus Therapeutics top institutional holders
InstitutionShares% HeldChange
MAK Capital One LLC33.62M12.62%0.0%
Blackstone Inc20.49M7.69%0.0%
Syncona Portfolio Ltd16.64M6.25%0.0%
Armistice Capital, LLC15.00M5.63%-5.1%
Tetragon Partners GP Ltd.9.50M3.57%0.0%
Schroder Investment Management Group7.83M2.94%-17.4%
Frazier Life Sciences Management, L.P. 4.45M1.67%0.0%
BNP Paribas Asset Management Holding S.A.3.36M1.26%0.0%
Laurion Capital Management, LP3.32M1.25%0.0%
Renaissance Technologies, LLC2.49M0.94%+25.6%

% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.

Top mutual fund and ETF holders of AUTL

Autolus Therapeutics top fund holders
FundShares% Held
iShares Trust-iShares Biotechnology ETF1.34M0.50%
Tema ETF Trust-Tema Oncology ETF268.13K0.10%
SPDR INDEX SHARES Fd.S-State Street SPDR S&P Intl Small Cap ETF101.95K0.04%
Invesco Exch-Trd Fd. TRT II-Invesco NASDAQ Future Gen 200 ETF50.74K0.02%
Trust for Professional Managers-ActivePassive International Equity ETF31.58K0.01%
Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund13.36K0.01%
Invesco Exchange-Traded Fund Trust II-Invesco Nasdaq Biotechnology ETF12.42K0.00%
ProShares Trust-ProShares Ultra Nasdaq Biotechnology8.01K0.00%

Frequently asked questions

Who is the largest shareholder of Autolus Therapeutics?

MAK Capital One LLC is the largest institutional shareholder of AUTL, owning 12.62% of shares outstanding (33.62M shares) as of its latest 13F filing.

What percentage of Autolus Therapeutics is owned by institutions?

Institutions own about 56.5% of AUTL shares and 69.5% of the public float.

How much of Autolus Therapeutics do insiders own?

Insiders, such as officers and directors, own about 18.73% of AUTL shares outstanding.

Where does institutional ownership data come from?

Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.

Related